Fifty-four patients (47 of whom were evaluable) with non-small cell lung cancer were treated with a five-drug regimen consisting of cyclophosphamide, vincristine, lomustine, cisplatin, and doxorubicin. Six complete and 16 partial responses were achieved, for an overall response rate of 47% (22 of 47 patients). Response by cell type was as follows: epidermoid carcinoma, 41% (seven of 17 patients); adenocarcinoma, 42% (eight of 19); and large cell carcinoma, 64% (seven of 11). Response in patients with limited disease was 48% (11 of 23 patients) and in patients with extensive disease, 46% (11 of 24). Previously untreated patients had response rates of 53%, versus 22% in those with prior therapy.